JP2019520393A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2019520393A
JP2019520393A JP2019500328A JP2019500328A JP2019520393A JP 2019520393 A JP2019520393 A JP 2019520393A JP 2019500328 A JP2019500328 A JP 2019500328A JP 2019500328 A JP2019500328 A JP 2019500328A JP 2019520393 A JP2019520393 A JP 2019520393A
Authority
JP
Japan
Prior art keywords
emulsion
pharmaceutical composition
pharmaceutically acceptable
cellulose
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019500328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520393A5 (https=
Inventor
クリスティアン・ヴォン・コルスヴァント
ロマン・ボルド
シモン・ペーテル・ミーエル・イェルム・ヨナソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2019520393A publication Critical patent/JP2019520393A/ja
Publication of JP2019520393A5 publication Critical patent/JP2019520393A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019500328A 2016-07-08 2017-07-06 医薬組成物 Withdrawn JP2019520393A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1611920.8A GB201611920D0 (en) 2016-07-08 2016-07-08 Pharmaceutical compositions
GB1611920.8 2016-07-08
PCT/EP2017/066983 WO2018015175A1 (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2019520393A true JP2019520393A (ja) 2019-07-18
JP2019520393A5 JP2019520393A5 (https=) 2020-08-06

Family

ID=56890842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500328A Withdrawn JP2019520393A (ja) 2016-07-08 2017-07-06 医薬組成物

Country Status (20)

Country Link
US (1) US20200254046A1 (https=)
EP (1) EP3481377A1 (https=)
JP (1) JP2019520393A (https=)
KR (1) KR20190026816A (https=)
CN (1) CN109414409A (https=)
AU (1) AU2017298873B2 (https=)
BR (1) BR112019000240A2 (https=)
CA (1) CA3029331A1 (https=)
CL (1) CL2019000042A1 (https=)
CO (1) CO2019000083A2 (https=)
CR (1) CR20190007A (https=)
DO (1) DOP2019000002A (https=)
EA (1) EA201990162A1 (https=)
GB (1) GB201611920D0 (https=)
IL (1) IL263999A (https=)
MX (1) MX2019000255A (https=)
PE (1) PE20190321A1 (https=)
PH (1) PH12019500024A1 (https=)
SG (1) SG11201811223YA (https=)
WO (1) WO2018015175A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071461A1 (ja) * 2020-10-02 2022-04-07 住友精化株式会社 粘性組成物
WO2022071463A1 (ja) * 2020-10-02 2022-04-07 住友精化株式会社 粘性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529945A (ja) * 2002-06-17 2005-10-06 リソルヴィックス ファーマシューティカルズ オメガ−３ｐｕｆａ由来の脂質メディエーターの類似体及び使用方法
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate
WO2010119319A1 (en) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
CN102512664B (zh) * 2010-12-31 2015-04-01 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071461A1 (ja) * 2020-10-02 2022-04-07 住友精化株式会社 粘性組成物
WO2022071463A1 (ja) * 2020-10-02 2022-04-07 住友精化株式会社 粘性組成物

Also Published As

Publication number Publication date
SG11201811223YA (en) 2019-01-30
AU2017298873B2 (en) 2020-04-30
EA201990162A1 (ru) 2019-06-28
WO2018015175A9 (en) 2018-03-29
IL263999A (en) 2019-01-31
BR112019000240A2 (pt) 2019-04-16
PE20190321A1 (es) 2019-03-04
PH12019500024A1 (en) 2019-11-04
MX2019000255A (es) 2019-05-27
CO2019000083A2 (es) 2019-01-18
EP3481377A1 (en) 2019-05-15
US20200254046A1 (en) 2020-08-13
CL2019000042A1 (es) 2019-04-12
KR20190026816A (ko) 2019-03-13
DOP2019000002A (es) 2019-03-31
CA3029331A1 (en) 2018-01-25
CN109414409A (zh) 2019-03-01
GB201611920D0 (en) 2016-08-24
AU2017298873A1 (en) 2019-02-14
CR20190007A (es) 2019-03-05
WO2018015175A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
You et al. Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion–solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil
US20220202768A1 (en) Dihydromyricetin nanoemulsion formulations and methods for forming them
US20100291200A1 (en) Formulations for poorly soluble drugs
CN105828806A (zh) 制剂
Chambin et al. Influence of cryogenic grinding on properties of a self-emulsifying formulation
JP7671693B2 (ja) 非クルクミノイドの水溶性粒子とクルクミノイドの水溶性粒子から構成される製剤
KR20220114639A (ko) 건강관리 제품에 사용하기 위한 계면활성제
CN102307576A (zh) 用于增强水不溶性活性剂的释放和吸收的方法
Abdallah et al. Development and characterization of controlled release ketoprofen microspheres
Singh et al. Sintering of wax for controlling release from pellets
Pohlen et al. Preparation, physicochemical characterisation and DoE optimisation of a spray-dried dry emulsion platform for delivery of a poorly soluble drug, simvastatin
CN1382061A (zh) 用于口服或局部给药的药物组合物
Shazly et al. Dissolution improvement of solid self-emulsifying drug delivery systems of fenofibrate using an inorganic high surface adsorption material
JP4028642B2 (ja) 乳化粉末の製造方法
Pohlen et al. A redispersible dry emulsion system with simvastatin prepared via fluid bed layering as a means of dissolution enhancement of a lipophilic drug
JP2019520393A (ja) 医薬組成物
Chambin et al. Dry adsorbed emulsion: 2. Dissolution behaviour of an intricate formulation
AU769541B2 (en) Spheronised self-emulsifying system for hydrophobic and water-sensitive agents
JP4282730B2 (ja) 乳化粉末の製造方法
Bhairy et al. Self-microemulsifying drug delivery system as carrier for the oral delivery of glimepiride: Formulation development, optimization, in-vitro characterization, stability assessment, ex-vivo permeation, and in-vivo antidiabetic activity in albino mice
Bhoyar et al. Encapsulation of naproxen in lipid-based matrix microspheres: characterization and release kinetics
Irshad et al. Probing the effect of various lipids and polymer blends on clopidogrel encapsulated floating microcarriers
Duclos et al. Rheology of polyol behenates and drug release from matrix monolithic capsules
RU2765946C1 (ru) Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления
Nguyen Extrusion-spheronization of pharmaceutical products: system for the delivery of active ingredients which are poorly soluble by oral route

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200623

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20201111